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Abstract
In the past decade, researchers have gained important insights on the role of bone marrow (BM)-derived cells in adult neovasculariza-
tion. A subset of BM-derived cells, called endothelial progenitor cells (EPCs), has been of particular interest, as these cells were sug-
gested to home to sites of neovascularization and neoendothelialization and differentiate into endothelial cells (ECs) in situ, a process
referred to as postnatal vasculogenesis. Therefore, EPCs were proposed as a potential regenerative tool for treating human vascular dis-
ease and a possible target to restrict vessel growth in tumour pathology. However, conflicting results have been reported in the field,
and the identification, characterization, and exact role of EPCs in vascular biology is still a subject of much discussion. The focus of this
review is on the controversial issues in the field of EPCs which are related to the lack of a unique EPC marker, identification challenges
related to the paucity of EPCs in the circulation, and the important phenotypical and functional overlap between EPCs, haematopoietic
cells and mature ECs. We also discuss our recent findings on the origin of endothelial outgrowth cells (EOCs), showing that this in vitro
defined EC population does not originate from circulating CD133 cells or CD45 haematopoietic cells.
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Introduction
The development of the vascular system is an essential event dur-
ing embryonic development of many animal species. During this
process, local mesodermal precursors differentiate into vascular
and endothelial cells (ECs) to form a primary vascular plexus, a
process referred to as vasculogenesis [1]. Until the description of
circulating endothelial progenitors (CEPCs), this process of vascu-
logenesis was thought only to occur during embryonic develop-
ment, but not in postnatal life. Indeed, a decade ago, two groups
reported that human CD34 cells isolated from circulating periph-
eral blood (PB), umbilical cord blood (UCB) and bone marrow
(BM), could differentiate into ECs in vitro and in vivo in mouse
models, thereby contributing to neoendothelialization and neovas-
cularization in the adult organism [2, 3]. Additional studies in mice
suggested incorporation of BM-derived cells into blood vessels at
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tumour sites [4, 5], healing wounds [6, 7], areas of endothelial
denudation [8, 9], induced hindlimb ischaemia [10] and following
experimental myocardial infarction [11].
These landmark studies on endothelial progenitor cells (EPCs)
thus challenged the traditional concept that endothelial regenera-
tion and angiogenesis occurs exclusively via the proliferation of
pre-existing resident vessel wall ECs, and thus it appeared that
vasculogenesis also occurs in postnatal life. Moreover, this novel
concept that EPCs enter the blood stream via the BM and provide
a pool of CEPCs in postnatal life was even more striking, because
there is no clear evidence that circulating vascular precursors con-
tribute to vasculogenesis during murine or human embryonic
development.
In patients that had undergone BM or PB stem cell transplan-
tation, evidence was also presented that some ECs lining the blood
vessels in the recipient were chimeric in origin, (i.e. of both recip-
ient and donor origin), pointing to the existence of circulating cells
in blood and BM that contribute to endothelial turnover of blood
vessels in humans [12, 13]. Indirect evidence for the concept that
EPCs act as a back-up system for maintaining vascular homeosta-
sis in humans was suggested by showing an inverse correlation
between the number of PB CEPCs and presence of atherosclero-
sis, an adverse cardiovascular risk score, level of cardiovascular
dysfunction, or cardiovascular morbidity and mortality risk in
human subjects [14–18]. Also, the functional properties of EPCs
such as cell adherence, migration, invasion and vessel formation
appear to be attenuated in patients with increased cardiovascular
risk factors and established cardiovascular disease [15, 19–21].
Therefore, EPCs could also serve as a biomarker to predict cardio-
vascular outcomes and might help in monitoring the effects of pri-
mary and secondary cardiovascular prevention strategies.
In spite of the growing number of reports on EPCs as a poten-
tial tool in regenerative medicine or a therapeutic target in oncol-
ogy, contradicting results have been reported at the pre-clinical
and clinical level, and several issues such as the definition, identi-
fication, characterization and the role of EPCs in vascular home-
ostasis and disease remain controversial [22–36]. In this review,
we will discuss these issues based on published results con-
ducted at the pre-clinical phase.
The proof-of-concept in vivo: the cell,
the read-out and the animal model
After 10 years of vigorous research in EPC biology, we have not
yet reached a consensus on the definitive appearance and function
of an EPC. What the field is currently suffering from is the use of
a single term (EPC) to refer to BM-derived or circulating cells of
diverse lineages. It is apparent that progress in the use of EPCs to
treat human disorders may not reach its ultimate potential unless
we can specifically identify all of the component cell types that
contribute to neovasculogenesis, define the role that each cell lin-
eage plays in the process, and identify strategies to assess the 
in vivo function of these diverse cell types in patients with vascu-
lar disorders, thus defining which cell type may need to be
replaced to reinvigorate the vascular repair process. Therefore, if
an EPC is defined as an immature precursor cell that individually
displays postnatal vasculogenic activity, then any cell called an
EPC should be capable of forming new ECs and blood vessels in
vivo. Unfortunately, attempts to illustrate this defining property of
a (candidate) EPC have often yielded conflicting results, which
probably relates to the highly variable approaches undertaken in
different research venues with regard to cell source, cell purifica-
tion, the animal model or assay used, method of detection and
analysis, and data interpretation.
The CEPC: still a putative cell
In many studies addressing the identity of EPCs in vascular biology,
unselected PB mononuclear cells (MNCs) were used, or the purity
of the (starting) CEPCs population was low, making it difficult to
identify the CEPCs within the MNC population that gave rise to the
ECs (i.e. the exact precursor (CEPC)–product (EC) relationship in
these studies was not addressed). Many investigators have identi-
fied or designated putative CEPCs with flow cytometry using a sin-
gle surface marker such as CD34 or CD133 in humans, or various
combinations of surface markers were used, which has actually
resulted in a complicated list of putative CEPC immunophenotypes
in man and mice (Table 1). As shown in Table 1, most of the surface
marker combinations used in flow cytometry studies included the
marker CD34 and vascular endothelial growth factor receptor-2
(VEGFR-2), because initial studies in the field have reported that
CD34 and VEGFR-2 cells purified from various sources (UCB, PB
and BM) are able to generate ECs in vitro, suggesting that CD34
cells contains CEPCs [2, 3, 37]. One specific subset of CD34 cells,
designated as CD34VEGFR-2CD133 cells are widely accepted
to identify ‘true CEPCs’ in humans but yet these cells were never
directly tested for generating new ECs in vitro or in vivo, which is
essential to validate CD34VEGFR-2CD133 cells as true CEPCs
[38–40]. Recently, however, Case et al. reported for the first time
that isolated human UCB or mobilized adult PB CD34VEGFR-
2CD133 cells in fact represent an enriched population of CD45
haematopoietic precursors using in vitro haematopoiesis assays,
but CD34VEGFR-2CD133 did not contribute to the formation of
ECs in vitro [41]. Similarly, CD34CD45CD146 cells previously
reported to represent CEPCs, were not directly assayed in vitro, nor
in vivo for contribution to newly formed endothelium, and thus, it is
difficult to know whether this cell type acts as a true CEPC [42]
Therefore, the scientific foundation for using the variable surface
marker combinations and CD34 subsets depicted in Table 1
remains elusive. Moreover, the use of these diverse combinations to
define a singular entity (the CEPC), makes the significance of flow
cytometric studies difficult to interpret, creates obstacles to the
direct comparison of data between laboratories, and may result in
discrepancies in the interpretations of study results among different
laboratories. Therefore, investigators should strongly consider that
any ‘putative’ CEPC, whatever its phenotype, be carefully assessed
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by validating its postnatal endothelial differentiation capacity in vitro
and in vivo.
A critical set of variables to consider when performing endothe-
lial differentiation studies is that putative CEPCs might only give rise
to ECs depending on the exact combination of growth factors to
which the cells have been exposed in vitro, and/or depending on the
animal model used to assess postnatal vasculogenic activity, and/or
the nature, extent, or method of delivery of the angiogenic stimulus
applied in vivo. These important caveats, in what should be the most
important criterion to validate EPCness, makes the field of EPCs
intriguing, but at the same time complicated. Therefore, further
efforts should be focused on the development of a straightforward
standard assay, or set of assays, that are accessible to all investiga-
tors, to specifically define and validate the function of (candidate)
EPCs, so that investigators would have a benchmark for compari-
son, and a rationale for the examination and clinical translation of
selected cell subsets in targeted clinical disorders.
To validate the EC differentiation capacity of a candidate CEPC,
single cell studies offer a rigorous approach to address the precursor
(CEPC)–product (EC) relationship However, numerous technical
and biological limitations must be overcome in performing a
clonal assay. For instance, one of the potential limits of single cell
experiments is that the isolated single cell may behave differently
in the absence of other cells. Therefore, transplanting or culturing
a single cell may not be an appropriate EPC assay, but may require
the presence of (supportive) cells with a different phenotype or
function. However, one of the greatest obstacles to date in the field
of EPC biology is the lack of a unique marker, or combination of
markers, that solely identifies the rare CEPCs in humans, making
a prospective isolation and thus single cells studies impossible. In
the murine BM transplantation system, two single cell transplan-
tation studies have been reported, showing that a single mouse
haematopoietic stem cell (HSC) could give rise to endothelial
progeny after retinal injury [43, 44]. However, these studies have
been challenged by other groups that failed to detect endothelial
differentiation from transplanted HSCs in vivo using different
donor cell marking strategies [23, 45].
Considering the remarks discussed in this section, two impor-
tant questions remain with regard to the phenotype of CEPCs: (i)
If CD34VEGFR-2CD133 appear not to be true CEPCs, what
Immunophenotype in humans Reference Immunophenotype in mice Reference
CD34CD31 [135] Sca-1 [10]
CD34CD62L [135] Sca-1 LincKit [145]
CD34CD133 [136]
CD34CD11b [137] Lin cKit Flk1 CD13 CD133VE-Cadherin [50]
CD34CD45 [110]
CD34 CD133CD45 [138]
CD34FGFR1 [111] CD45dimCD34 Flk-1 [9]
CD34VEGFR-2 [112] CD31Flk-1CXCR4 [146]
CD34CD133VEGFR-2 [38] Sca-1cKitLin [56]
CD34CD133VEGFR-2 [55] CD45CD34Flk-1 [98]
CD34VE-CadherinCD3 [139] cKitCD31 [147]
CD34CD133VEGFR-2CD45 [40] cKitCD34Flk-1 [148]
CD34CD45CD146 [42] CD45cKitCD13 [149]
CD34CD45 [140]
CD133 [17]
CD133CD45 [141]
CD133VEGFR-2 [142]
CD14VEGFR-2 [71]
CD14CD34 [70]
ALDHbright [143]
CD31 [144]
Table 1 Surface immunophenotype of human and murine CEPCs
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then is the exact surface phenotype of the CEPCs? and (ii) How
can we explain the statistical (inverse) correlation between the
several cell subsets depicted in Table 1 and cardiovascular indices
and outcome, even if these cell types would not represent true
CEPC? As we will discuss later in this review, the phenotypes
shown in Table 1 mostly represent haematopoietic-derived cells,
rather than true CEPCs, similar to the CD34VEGFR-2CD133
cells discussed above. Nevertheless, haematopoietic-derived cells
may contribute to vascular repair and homeostasis in an indirect
manner, as suggested by several investigators [25, 31, 46–48].
Indeed, haematopoietic lineage cells might be recruited to injured
or angiogenic sites and secrete regulatory cytokines that promote
vessel homeostasis and repair by local cells, including local ves-
sel wall ECs. It is possible that cardiovascular risk factors and
established cardiovascular disease decrease the circulating num-
ber and properties of the haematopoietic-derived cells. Hence, low
levels of these circulating cells might correlate with adverse car-
diovascular outcome. However, this concept is entirely different
from the EPC concept proposed 10 years ago where EPCs were
suggested to function as a structural backup from the BM [2].
The question as to what the exact phenotype is of true CEPCs
will be discussed at the end of the review after we have outlined
several crucial issues related to the identification, definition and
differentiated progenies of putative CEPCs.
Do CEPCs play an essential role in vascular 
(patho)physiology?
Although many papers have been reported on EPCs in man and
mice, the direct proof-of-concept or true relevance of these cells in
vascular homeostasis, vascular growth and disease (atherosclero-
sis) is still uncertain. Perhaps one of the most solid approaches to
address the relevance of CEPCs in vascular homeostasis is to look
at the natural history of vascular aging or the extent of vascular dis-
ease in animal models lacking these CEPCs. This could be achieved
by selectively eliminating the CEPCs in mice with pharmacological
agents, or by means of genetic knockdown. The vascular outcome
in mice with knockedout EPCs could then be compared with control
mice in diverse pathological settings. However, (genetic) knock-
down studies to assess the mechanistic underpinning between
CEPCs and vascular (patho)biology, requires that one possess the
ability to prospectively identify and thus specifically target the
CEPCs, without targeting the mature vessel wall ECs. Indeed, the
current approaches used to abolish or enhance the function and/or
number of endogenous CEPCs might not have been selective
enough, and are likely to have targeted mature vessel wall ECs, and
other (BM-derived) cells involved in vascular repair as well, thus
complicating the interpretation of the study results of CEPCs in
modulating the process of vascular repair [49]. Recently, some
studies have focused on the role of CEPCs in tumour angiogenesis
in murine models using several knockdown tools [5, 50, 51]. In
these studies, murine BM-derived CEPCs were immunophenotyped
as cKitFlk-1CD13CD133 cells. Moreover, it was suggested
that these candidate CEPCs express Id-1 proteins and a monomeric
form of the surface markers VE-Cadherin (i.e. CD144) in a unique
fashion, whereas the resident mature ECs did not. This allowed the
investigators to selectively inhibit the CEPCs without targeting the
resident mature vessel wall ECs, and thus address the relevance of
CEPCs in tumour angiogenesis. However, studies have shown that
local, mature vessel wall ECs also express the monomeric VE-
Cadherin epitope upon vessel disassembly and tumour angiogene-
sis [52]. Therefore, it is possible that the neutralizing antibody used
to target the CEPCs might also have tackled the proliferating mature
vessel wall ECs in this study [52].
In another study, it was suggested that murine CEPCs selec-
tively express Id-1, a protein previously shown to be involved in
angiogenesis [4, 51]. Using genetically manipulated BM cells, the
expression of this Id-1 gene could be turned off ‘à la demande’,
resulting in a profound reduction of tumour angiogenesis and
tumour growth. However, because Id-1 is also expressed in
haematopoietic lineage cells, it remains uncertain whether the
inhibition of tumour angiogenesis is merely because of reduced
tumour-recruitment and/or paracrine angiogenic function of
haematopoietic lineage cells, instead of reduced CEPC function,
differentiation or incorporation [50, 53]. Therefore, although
these studies illustrate the role of BM cells in tumour angiogene-
sis, because of a lack of specificity, they do not formally prove the
unique or dominant position of putative CEPCs in the modulation
of tumour angiogenesis. Therefore, at the end, the identification
of a unique marker gene that specifically identifies CEPCs will
allow us to unambiguously address the ‘proof-of-concept’ or
causal role of CEPCs in cardviovascular (patho)physiology and
tumour pathology.
In Figure 1, we propose a genetic knock-down model based on
the expression of a unique cell marker in CEPCs (being either a
Fig. 1 Conditional EPC knockout mouse model based on a unique CEPC
marker. A modified estrogen receptor (mER; in red) is co-expressed on
CEPCs that expresses a unique marker (indicated in grey). This unique
marker may be either a membrane (as shown) or a cytoplasmatic marker.
Upon challenge with a receptor specific agent, the mER activates the Cre
enzyme (indicated by scissors) in CEPCs. The Cre-enzyme recognizes the
specific LoxP sequences (white) that flank a survival gene (black) result-
ing in its deletion and eventually CEPC death.
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surface or intracellular marker). As illustrated, in this conditional
knock-down model, only CEPCs that express a unique marker
gene will be targeted and die after challenge with the specific
agent, whereas mature vessel wall ECs and haematopoietic cells
that do not express this unique cell marker, will not be targeted.
Comparative studies between knockedout mice and control mice
will then accurately answer the question whether CEPCs are truly
causal or act as an essential backup for vascular disease and
physiology, respectively.
The in vivo read-out and animal model
Perhaps the most important but often disregarded issue in the
assessment of the precursor–product relationship are the criteria
used to identify the EPC progeny as ‘true ECs’ in vivo. In fact, iden-
tifying a cell as a bona fide EC is crucial for classifying its precur-
sor as a true EPC. To identify ECs generated from CEPCs in vivo,
most reports have relied on the anatomical position of the donor
cell population within the context of a perfused vascular structure
in combination with a single marker or combination of cell surface
markers that typically are expressed on normal vascular ECs such
as CD31 or CD34, or the uptake of acetylated low density lipopro-
tein (LDL), as well as the binding of certain plant lectins (Ulex
Europaeus Agglutinin-1 or UEA-1) to identify ECs [54–56].
However, most of the characteristics, or cell markers used in
 previous studies such as CD31, CD34, lectin binding or LDL
 ingestion, are not specific for the endothelial lineage, but also
characterize haematopoietic lineage cells (Table 2) [57, 58]. This
notion is important because vascular homeostasis and repair are
Embryonic HPC Postnatal HPC ECs References
CD14 – – – [58, 85]
CD31 (PECAM-1)    [58, 85, 106, 150]
CD34    [41, 106, 109, 150, 151, 152, 153]
CD38 –/ –/ – [152, 153]
CD43   – [109, 151]
CD44 ?  ? [153]
CD45 –/  – [41, 58, 106, 108, 109, 153]
CD54 (ICAM-1) ?   [154]
CD90   ()a [109, 153]
CD105 (Endoglin) ?   [58, 155]
CD106 (VCAM-1) ? ? ()b [133]
CD117 (C-kit)   ()a [58, 79, 151, 153]
CD133 (?) c  – [58, 153]
CD143   ? [156]
CD146 (MUC-18) ? ?  [58]
CD164   – [157]
VEGFR-2  ()d ()e [58, 106, 132, 151]
Tie-2    [106, 158]
VE-Cadherin (CD144)  –  [58, 106, 109]
Table 2 Immunophenotype of haematopoietic cells and endothelial cells
Note: The surface marker profile of human embryonic haematopoietic precursors (HPC), postnatal HPCs and ECs is depicted. The surface marker
profile of the EC markers shown is based on the analysis of both in vivo ECs and in vitro cultured vessel wall ECs. 
()a indicates that we identified a small CD90 or CD117 population on non-passaged vessel wall ECs. 
()b indicates that CD106 is upregulated following endothelial activation [133]. 
()c indicates that the haematopoietic potential (T cells) of embryonic stem cell-derived CD133 HPCs has been demonstrated only in vivo [134]. 
()d refers to a report on the expression of VEGFR-2 on a small HSC population [132]. 
()e indicates that the precursor–product relation between circulating VEGFR-2 cells and EOCs generated in vitro has not yet been proven.
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multi-cellular processes, recruiting several cellular participants
such as local vascular wall cells (vessel wall progenitors, smooth
muscle cells, pericytes, ECs and macrophages) and circulating
BM-derived cells, including putative CEPCs, but also haematopoi-
etic (derived) cells [22, 25, 31, 32, 59, 60–63].
Mature haematopoietic cells include red blood cells, platelets,
myeloid cells such as monocytes/macrophages and granulocytes,
dendritic cells and lymphoid cells including B cells, T cells, NK cells
and NKT cells. Haematopoietic cells derive from HSCs and
haematopoietic progenitor cells (HPC respectively) that reside
within the BM. Importantly, haematopoietic-derived cells such as
monocytes, granulocytes, platelets and even HSCs/HPCs have
been shown to be involved in vascular repair [48, 64]. However,
because both endothelial lineage cells and haematopoietic cells are
present at sites of neovascularization and co-express a host of sim-
ilar surface markers, it might be difficult to discriminate them from
each other at sites of vascular repair, and appreciate their individ-
ual contribution to the healing or regenerative process. Therefore,
the diverse recruited cell types now known to populate sites of neo-
vascularization are highly likely to have previously been lumped
into the single term ‘EPC’ in many early studies of postnatal vascu-
logenesis, explaining some of the apparent controversy in the field.
One of the strategies that have been used to directly assay
donor cell differentiation into ECs in vivo has been the use of trans-
genic mice that express a fluorescent marker (e.g. green fluores-
cent protein (GFP)) only in cells expressing an endothelial specific
gene, such as Tie-2 [65]. Therefore, transplantation of BM cells
from transgenic mice into wild-type mice allows the tracking of the
cells of interest, and their fate during mobilization from the BM into
sites of vascular injury, and discriminates them from other cell
types and host cells involved in vascular repair and regeneration.
However, even these sophisticated approaches have often yielded
contradictory results, probably because expression of Tie-2 is not
entirely restricted to the endothelial lineage, and is also expressed
by pericytes and haematopoietic (derived) cells such as mono-
cytes, that also migrate to sites of vascular repair [22].
On the other hand, it has been argued that the failure to retrieve
genetically labelled BM-derived Tie-2 ECs in the paper of De
Palma et al. might be because of the fact that the exogenous Tie-
2 promoter used, may not mark all the mature ECs, or that during
the random genetic manipulation of the cells, the CEPC population
might not have been targeted with the viral Tie-2 vector [5]. Also,
it is possible that the failure to detect few, if any BM-derived ECs
in the neovasculature of experimental models may be related to
poor engraftment of the EPC compartment following their trans-
plantation [22, 66]. Although the latter pitfall can be circumvented
by the use of a parabiosis model (where two mice are surgically
connected and share a common circulatory system allowing
exchange of circulating cells), conflicting results have also been
reported in the parabiosis model [36].
To unequivocally illustrate in vivo that the EPC-derived progeny
in the newly formed vasculature is truly endothelial in nature, a
more direct or convincing approach would be the extraction of
putative EPC progeny from the tissues (by means of a genetic
tracer such as GFP) and FACS analyse (with and without previous
culture) these cells using a wide panel (CD11, CD45, VE-Cadherin,
CD146, CD31, CD13, CD105, etc.) of antigens and combinations
of these markers to illustrate their true endothelial lineage and dis-
criminate them from other cell lineages, especially the
haematopoietic lineage. In addition, these extracted cells could
also be tested functionally by means of proliferative capacity or
tube forming capacity. So far, only one group has used such a
FACS strategy to identify EPC progeny in vivo [5], but the marker
combination used (CD31LectinGFP) does not allow a clear
discrimination from haematopoietic (derived) cells that also dis-
play these properties [5, 57].
Other methodological issues, such as the number of tissue
sites sampled, or the time frame of the study intervals, and the
microscopic technique employed in the tissue analysis, may
explain the variable results of EPCs to contribute to sites of neo-
vascularization in different animal model systems. For instance,
while the use of confocal microscopy may permit a complete vol-
umetric three-dimensional rendering of the donor cell contribution
to new blood vessels in a damaged tissue, the use of light
microscopy might impose difficulty in discriminating whether
cells are incorporated at the luminal layer and are integrated within
the endothelial layer, or are located at peri-luminal sites, just
beneath the endothelial layer [22, 28]. Therefore, differences in the
microscopic technique, and/or method of analysis of the imaging
data, may also contribute to the highly variable reported rate of
incorporation of EPCs in repairing vessels (0–90%). Furthermore,
it remains uncertain how many of the ‘luminal integrated cells’
(e.g. monocytes, that phenotypically overlap with ECs) are in fact
passenger cells participating in an inflammatory reaction to the
vascular injury, or cells in the process of transmigrating deeper
into the vessel wall and interstitial tissues. Thus, whenever possi-
ble, the use of three-dimensional imaging may provide the most
sensitive and specific information on the location and contribution
of the donor cells to tissues under repair (given the use of appro-
priately tested antibodies that are specific and validated for detec-
tion of cells, cell nuclei or organelles, basement membrane and
extracellular matrix proteins).
Other variables that must be considered when using animal
models include the genetic background of the mouse, the type of
vascular injury to be incurred and the organ system to be chal-
lenged. In the case of a tumour model system where one wishes
to examine donor cell contributions to tumour endothelium, the
tumour type, stage and therapy may be important [5, 49]. Also,
the nature of the angiogenic stimulus may be critical, because the
cellular and molecular mechanisms of (neo)vascularization differ,
depending on whether a tumour, a denuded artery, a myocardial
infarction, hindlimb ischaemia or a traumatic injury is used to
assay a candidate EPC [67, 68]. Therefore, specific cell subsets
may be recruited preferentially, and conflicting results may ensue,
depending on the animal or tissue model.
Also, the degree of EPC contribution may also depend on the
type of vascular bed that has been studied. Indeed, the degree of
CEPC incorporation and contribution to neovessels may be influ-
enced by competition between CEPCs and the resident ECs during
vascular repair and regeneration.
J. Cell. Mol. Med. Vol 13, No 1, 2009
93© 2009 The Authors
Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Summarizing this section, it is imperative that improved
approaches are developed to reconcile the previous conflicting
reports on the role of EPCs in vascular repair, to further define the
exact immunophenotype of CEPCs, and to define other participat-
ing cell types in adult vessel repair and regeneration.
EPCs defined in vitro:
the Achilles heel in EPC biology
EOCs and EC-like cells
Most investigators have focused on the study of ‘EPCs’ obtained
after the ex vivo culture of unfractionated MNCs that contain puta-
tive CEPCs. This is because CEPCs appear to be present in the 
circulation at very low numbers, requiring ‘ex vivo culture’ to
obtain sufficient numbers to characterize and study them in dis-
ease models. Numerous assays have been developed to plate
MNCs in specific conditions to ‘make putative CEPCs differentiate
into ECs in vitro’ [2, 3, 37, 38, 55, 69–72], ‘to expand CEPCs ex-
vivo’ [73–76], or to ‘assay CEPCs for colony forming capacity’ [17,
77–79]. Irrespective of the assay or the purposes of the EPC cul-
tures reported so far, two major cell types have been shown to
emerge out of these MNC cultures: (1) cells that display a mixed
endothelial-monocytic/haematopoietic phenotype [47, 57, 58, 74,
76, 80–86] which we refer to as EC-like cells, and (2) cells with
high proliferative potential that display typical endothelial charac-
teristics, reminiscent to vessel wall ECs, which we refer to as
endothelial outgrowth cells (EOCs) [37, 58, 75, 79, 81, 85–88].
The nomenclature used to describe each major cell type has
been widely varying and often intermixed (Table 3), which has con-
tributed to the confusion in this field. Also, in many of the early stud-
ies of EPC biology, it has been impossible to appreciate the exact
EC-like cells EOCs CECs
(EPCs, ECs, CFU-ECs, CACs, ATs, early out-
growth CE-EPCs, CMMCs and early EPCs)
(EPCs, ECs, CFU-ECs, BOECs, ECFCs, EPDCs,
EC-like, late EPCs, late endothelial outgrowth)
(Circulating endothelial cells)
1. Generated after 4–21 days in culture 1. Appear after  7 days in culture 1. Low proliferative ECs, shed from the vascu-
lar wall into the circulation
2. Round (pancake) to spindle shaped appear-
ance; no typical confluent monolayer
2. Typical polygonal cells in a confluent cob-
blestone monolayer
2. Have a similar phenotypical profile com-
pared to EOCs
3. Express endothelial and haematopoietic
markers (e.g. CD45, CD14)
3. Express CD31, CD34, CD105, CD146, VE-
Cadherin, VEGFR-2, but not the
haematopoietic surface markers CD133,
CD14 or CD45
3. Do not express haematopoietic markers
and have no apparent haematopoietic
potential or function
4. Bind UEA-1 lectin and take up LDL 4. Bind UEA-1 lectin and take up LDL
5. Maintain haematopoietic potential and/or
functions
5. Have no apparent haematopoietic potential
6. Have low proliferative potential 6. Bear high proliferative potential
7. Do not generate vascular tubes in vitro in
matrigel
7. Generate vascular tubes in vitro/in vivo in
matrigel
8. Improve neovascularization in vivo 8. Improve neovascularization in vivo
9. Originate from CD45+ haematopoietic line-
age cells (CD34+CD45+, CD133+CD45+,
CD34CD45+, CD14+CD45+)
9. Originate from CD45CD133CD34+ cells,
bone marrow (*) and probably the vascular
wall
Table 3 Characteristics of human EC-like cells, EOCs and CECs
CFU-ECs [77, 159, 160]: colony forming unit of endothelial cells; ATs [161]: attaching cells; CACs [47]: circulating angiogenic cells; CE-EPCs [76]:
culture expanded endothelial progenitor cells; CMMCs [162]: culture modified mononuclear cells; EOCs [58]: endothelial outgrowth cells; BOECs
[163]: blood EOCs; ECFCs [79]: endothelial colony forming cells; EPDCs [37]: endothelial progenitor-derived cells; CECs [163]: circulating
endothelial cells,
(*) [94]: bone marrow multipotent adult progenitor cells (MAPCs) have been suggested to be the earliest
EOC precursors.
References: [30, 37, 41, 42, 47, 57, 58, 74–76, 79, 80, 82–86, 95, 117, 119, 131, 163].
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cell type (EC-like cells versus EOCs) obtained in vitro, owing to the
limited characterization of the cells described in the reports. Indeed,
both EC-like cells and EOCs express several identical surface
 markers such as CD31, lectin binding, vWF and uptake of LDL [57].
However, recent studies have shown that EC-like cells do not
 represent true ECs and derive from heterogeneous
CD45haematopoietic cells, including CD34CD45(CD133)
HSCs/HPCs and CD45CD14 monocytic cells that both co-
express a set of ‘endothelial’ surface markers [57, 58, 85].
Therefore, we encourage the use of extensive criteria, as depicted in
Tables 2 and 3 that allows for an accurate discrimination between
these two cell types in vitro. This discrimination is based on pheno-
typical, morphological and functional characteristics typical for cul-
tured vessel wall ECs. However, it is important to note that the mark-
ers depicted in Tables 2 and 3 are not uniformly expressed by all ECs
lining the blood vessels in vivo, and ECs may change their surface
marker expression profile upon ex vivo culture [89, 90].
Nevertheless, ECs in vivo have many characteristics in common
similar to the in vitro defined EOCs, as described in Tables 2 and 3
[37, 79, 85, 91, 92]. Therefore, apart from their vessel forming abil-
ity, it has been stipulated that cells can be ascribed as ‘true EPCs’
only if they generate true ECs sharing most of these characteristics
[57, 86, 87, 93–95]. Conversely, the circulating cells that generate
EC-like cells in vitro cannot be considered as true CEPCs [57].
In the murine system, similar EOCs and EC-like populations
have been described in vitro, or at least the same nomenclature
has been used to describe similar endothelial progenies. Similar to
the human situation, early EPCs have been shown to derive from
haematopoietic precursors [96]. So far, murine MNCs have been
plated to obtain EOCs, but it is unknown what the exact phenotype
is of the circulating cell (see the putative murine CEPCs pheno-
types in Table 1) that gives rise to these murine EOCs in vitro (i.e.
a precursor–product relationship is completely lacking) [97, 98].
With regard to the role in neovascularization in vivo of both in
vitro generated EOCs and EC-like cells, conflicting schools of
thought exist. There is evidence that injected (in vitro generated)
EC-like and EOCs act in synergy during vascular repair. EOCs
appear to structurally contribute to neovessels, whereas EC-like
cells do not directly contribute to the neovessels, but rather, act in
an indirect paracrine fashion by locally secreting angiogenic sub-
stances that promote structural healing by resident ECs and incor-
porated EOCs. Because the incorporation and direct structural
contribution to neoendothelium has been claimed to be a major
criterion for defining a cell as an EPC, some have redefined EC-like
cells as ‘angiogenic cells’ instead of EPCs, because they do not
directly participate in neovascularization, and therefore, do not act
as true EPCs in the literal sense (i.e. structurally contribute to
neovessels) [47, 57, 99]. In fact, this redefinition is in agreement
with studies in the embryo [46] and adulthood [23, 25, 45], show-
ing that (non-cultured) haematopoietic lineage cells (that give rise
to EC-like cells in vitro) do not structurally contribute to growing
vessels, but rather, act in a indirect, instructive manner to help in
neovascularization. However, disagreement persists in the scien-
tific community with respect to this redefinition and a consensus
in the field is far from unanimous.
What are potential caveats with in vitro defined cells?
An important drawback in the study of cultured cells is that ‘EC-
like cells’ and ‘EOCs’ may have acquired or lost properties during
culture that influence experimental outcomes (in a positive or neg-
ative way) compared to their non-cultured counterpart (i.e. the cir-
culating cells from which they originate, which are in fact the cells
of true interest, the EPC). In other words, the function (e.g. vascu-
logenic and incorporation properties) and phenotype (e.g. surface
marker profile) of in vitro propagated endothelial lineage cells may
be culture artefacts compared to their in vivo counterpart. In fact,
this question is relevant to any in vitro defined cell population and
should cause one to be careful in directly comparing the role, phe-
notype and function of cultured cells with respect to their original
in vivo (non-passaged) precursors [90, 100]. More specific to the
field of EPC biology, two reports showed that injected, non-cul-
tured CD14 monocytes did not enhance or incorporate into
neovessels, whereas their in vitro derivates did [76, 84]. This
might indicate that native monocytes are already present abun-
dantly at sites of tissue healing [25, 63] or that monocyte-derived
EC-like cells are culture artefacts with altered properties (not nor-
mally present in vivo) induced by the culture conditions, and
might not exist as such in vivo.
The search for the EOC precursor: lessons from
embryonic development
The close developmental association, surface marker, and molec-
ular overlap between haematopoietic cells and ECs supports the
concept of the haemangioblast as being the bipotent predecessor
for both haematopoietic cells and ECs (see Fig. 2) [101]. Although
many studies support the haemangioblast concept in vitro,
whether this cell exists as a distinct entity during embryonic devel-
opment in vivo and whether it persists into adulthood remain a
subject of great debate [102–105]. In fact, some groups have
shown evidence for the existence of ‘haemogenic endothelial cells’
(HECs) (that express the markers CD31, CD34, VEGFR-2 and VE-
Cadherin) [106], which provides an alternative explanation for the
developmental overlap between haematopoietic and ECs (i.e.
these ‘unipotent’ transitional ECs instead of haemangioblasts dif-
ferentiate into haematopoietic progenitor cells (HPCs) in the
embryo, see Fig. 2) [107].
We have used some of the strategies previously utilized to
define the embryonic ‘haemangioblast’ and ‘HECs’ to address
the phenotype of the cell(s) that give rise to EOCs in the human
adult, with specific emphasis on the common leucocyte marker
CD45, as a defining marker [58]. Both the embryonic haeman-
gioblast and HECs express VEGFR-2 and CD34, explaining why
these markers have been popular to identify CEPCs in the
human adult [106, 108, 109]. Importantly, studies in haemato-
endothelial development have shown that CD34 embryonic
haemangioblasts or HECs do not express the common leuco-
cyte antigen CD45, but acquire this marker only during differen-
tiation into HPCs (and thus become CD34CD45), but not during
commitment into the endothelial lineage (Fig. 2) [106, 108,
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109]. Therefore, CD45 expression marks haematopoietic speci-
fication from foetal life into adulthood, while it is not expressed
on endothelial lineage cells (Table 2). The developmental over-
lap, the common surface marker expression on HSCs/HPCs and
ECs, and the findings that CD34 cells can generate both
haematopoietic and endothelial progeny in the adult [37] has led
investigators to believe that CD34CD45 HSCs/HPCs display a
‘haemangioblastic’ or ‘EPC capacity’ in human postnatal life [3,
110]. However, analysis of the marker CD45 was not performed
in the original description of CD34 CEPCs [2, 3, 38, 111, 112].
This is a major limitation because CD34 cells in the adult not
only contain CD34CD45 HPCs but also a small CD34CD45
cell fraction, similar to the embryonic situation. Importantly, we
showed that the CD34CD45 cell fraction, but not
CD34CD45 haematopoietic cells within CD34 cells gener-
ates EOCs [41, 58]. Therefore, if EOCs are considered to be
derived from true CEPCs, these cells should be contained within
the CD34CD45 cell fraction, but not within the CD34CD45
haematopoietic cell fraction. Indeed, we showed that the
CD34CD45 HSC/HPC cell fraction did not generate EOCs, but
differentiated into EC-like cells through a CD14 monocytic
pathway [58].
We also detected the marker VEGFR-2 in the CD34CD45 cell
population, a tyrosine kinase receptor indispensable for both
endothelial and haematopoietic lineages [113, 114]. However,
CD34VEGFR-2 cells within the CD34CD45 cell fraction may
represent ‘mature’ ECs [39], or CD34VEGFR-2 cells that co-
express CD133 may represent the pool of CEPCs [38, 39]. Indeed,
because the CD34VEGFR-2 phenotype may also represent
mature ECs, Peichev and co-workers have proposed that
CD34VEGFR-2 cells co-expressing CD133 represent true
immature CEPCs. Upon differentiation into mature ECs,
CD34VEGFR-2CD133 CEPCs are believed to lose expression
of CD133. This is corroborated by the fact that mature ECs lining
the blood vessels in the adult organism neither express the CD133
protein [38]. However, we showed that the EOC-generating
CD34CD45 cell fraction does not express CD133 [58]. In fact,
several other investigators have been unable to detect the CD133
antigen on CD34CD45 cells, which confirms our findings [42,
115, 116]. As such, the surface antigen CD133 cannot be used to
identify putative circulating EOC-precursors. In fact,
CD34VEGFR-2CD133 cells were recently shown to be
CD45 haematopoietic progenitors instead of true CEPCs and do
not generate EOCs [41, 58]. Therefore, previous reports showing
that CD34 (CD45) HPCs contain EPCs or haemangioblasts,
and that CD133 cells can differentiate into ‘ECs’ can be chal-
lenged with respect to the specific CD34 subpopulation studied,
and/or the criteria used to identify endothelial progeny as bona
fide ECs (see Table 3).
Do EOCs derive from an immature CEPC?
The developmental and maturation from ‘stem cells’ or ‘progeni-
tors’ into ‘mature cells’ is well established in many developing sys-
tems, and is characterized by a stepwise loss and gain of specific
markers, and/or cell functions. However, because of the lack of a
marker that discriminates circulating EOC-precursors from in vitro
cultured EOCs, the exact identity of circulating EOC-precursors
remains uncertain. As a consequence, it is unknown whether
CD34CD45 EOC-precursors are distinct from EOCs generated
in vitro with respect to phenotypical and functional characteristics.
In other words, it is unknown whether the EOCs ‘generated’ or
‘expanded’ ex vivo represent the differentiated progeny of a dis-
tinct, undifferentiated precursor and whether EOCs are just circu-
lating mature ECs.
Nevertheless, it has been claimed that EOCs are a CEPC-
derived population based on functional differences between EOCs
Fig. 2 Haemato-endothelial developmental pathways and their relation to
the expression of CD45.
In the embryo, CD45 mesodermal precursors give rise to CD45
endothelial precursors (EPCs), haemangioblasts and/or haemogenic
endothelial cells (HECs). The CD45 EPCs differentiate into functional
and mature ECs. Embryonic haemangioblasts are CD45 and differenti-
ate to both CD45 endothelial lineage cells and CD45 HSCs/HPCs 
in vitro. Alternatively, or in addition to haemangioblasts, CD45 HECs give
rise to CD45 haematopoietic stem/progenitor cells. HSCs/HPCs can
give rise to EC-like cells in vitro and retain expression of CD45, whereas
expression of the CD133 antigen is downregulated.
96 © 2009 The Authors
Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
and ‘control’ mature vessel wall ECs such as human umbilical vein
endothelial cells (HUVECs). In these studies, EOCs displayed a
higher proliferative potential, angiogenic cytokine release and
stress resistance compared to HUVEC and other vessel wall ECs
[37, 88, 117]. However, conflicting results have been reported on
these characteristics and these findings do not allow us to con-
clude that EOCs are an EPC-derived cell population [118]. Indeed,
to address EPCness of EOCs, the most straightforward approach
would be the direct assessment of EOCs (head-to-head with
mature vessel wall ECs) in in vivo vasculogenic assays in mice
such as experimental myocardial infarction, hind limb ischaemia
and other clinical relevant conditions.
To date however, only one study has reported enhanced vessel
forming ability of EOCs compared to ‘mature’ vessel wall ECs in an
ischaemic mouse model [119]. All other studies have categorized
EOCs as EPCs or an EPC-derived population based on vasculogenic
properties assayed in in vivo and in vitro matrigel assays [57, 120].
In the matrigel assay, endothelial lineage cells are incubated in an
extracellular matrix derived from murine sarcoma cells that sup-
ports vascular tube formation. Vascular tube formation in matrigel
is thought to recapitulate in vivo vasculogensis and angiogenesis.
However, the relevance of matrigel assays for addressing EPCness
of EOCs is cumbersome, because ‘mature ECs’ such as HUVECs
were also shown to robustly incorporate and generate vascular
tubes using a matrigel assay in vivo [57, 120].
Therefore, more experimental data are required to document
incorporation and regeneration of durable blood vessels by
injected EOCs (and compared with mature vessel wall ECs such as
HUVECs) in several relevant in vivo models. Moreover, because 
in vitro cultured EOCs may have decreased vasculogenic proper-
ties (‘decrease of EPCness’) compared to their in vivo EOC-precur-
sors, the identification of a specific EOC-precursor marker would
allow the isolation of EOC-precursors and test them in these
assays and directly compare them with cultured EOCs and mature
vessel wall ECs.
Do EOCs derive from high proliferative vessel wall ECs?
Because EOCs display striking similarities with ‘mature vessel wall
ECs’, one may speculate whether blood-derived EOCs are just ‘cul-
ture-expanded’ mature ECs that have dislodged from the vessel
wall (e.g. at angiogenic sites, during increased shear stress, vein-
puncture related etc. [121, 122]), rather than being the differenti-
ated progeny from a CD34CD45 BM-derived immature CEPC.
Indeed, it is known that ECs can detach from the vessel wall into
the circulation in normal physiology and during several clinical
disorders [123]. These vessel wall dislodged ECs, designated as
circulating ECs (‘CECs’), have been claimed to be ‘mature ECs’, but
the general view is that these CECs do not give rise to EOCs 
in vitro because CECs bear no or low proliferative potential,
whereas EOCs bear high proliferative potential [123]. In fact, in a
seminal report studying sex-mismatched BM transplant patients,
Lin et al. claimed that EOCs originate from putative BM precur-
sors, whereas CECs with low proliferative potential originate from
the vessel wall [87].
However, it is possible that the myeloablative procedure in
this study might have attenuated the proliferative capacity of the
recipient’s vessel wall ECs, therefore neglecting other sources
for EOCs than the BM, such as the vessel wall. Indeed, vessel
wall ECs such as HUVECs have been shown to expand to simi-
lar levels compared to blood-derived EOCs, indicating that
‘mature’ vessel wall ECs do have a robust proliferative potential
and may be at the origin of EOCs [37, 124–126]. This has been
corroborated by a recent single cell study showing that ECs of
the adult vessel wall display a proliferative hierarchy ranging
from non-replicating ECs, to very high proliferative ECs [127].
Notably, we also found that 2% of freshly isolated HUVECs have
a similar expansion potential compared to UCB-derived EOCs at
the single cell level (F. Timmermans, unpublished observation).
Although these findings suggest that EOCs cultured from circu-
lating blood derive from high proliferative vessel wall ECs or
true resident vessel wall EPCs (that both can enter into the
bloodstream), this issue needs to be clarified. Furthermore, it
remains to be seen whether high proliferative vessel wall ECs
originally derive from incorporated BM precursors or not.
Finally, it would be interesting to know whether BM EOC-precur-
sors are located in the haematopoietic niche of the BM, or
reside with the BM vessel wall.
CEPCs and CECs: functionally different cells having 
the same identity?
It is common use to indicate CECs as vessel wall ECs with low
proliferative potential that preferentially slough off from the ves-
sel wall during normal and pathological conditions [123].
Although several studies have suggested that the number of
CECs is increased in some disorders [123], there has been a
parallel debate on how ‘CECs’ should be defined from an
immunophenotypic point of view (see reference [128] versus
[129]), an obstacle reminiscent to the field of CEPCs. Moreover,
our data showing that putative CEPCs (EOC-precursors) reside
in the CD45 cell fractions, and do not express CD133, further
complicates the immunophenotypic discrimination between
‘CECs’ and ‘CEPCs’, because to date, the markers CD133 and
CD45 were thought to discriminate putative CEPCs from CECs
[39, 130, 131]. Also, the claim that CEPCs tend to be smaller
cells compared to CECs, has not yet been validated given the
lack of a clear precursor–product relationship that included this
parameter in vitro as well as in vivo, as discussed in the first
section of this review.
To date, the literature in the field of EPCs supports the marker
combination CD34VEGFR-2 to identify CEPCs in humans
[112]. However, circulating CD34VEGFR-2 cells may also rep-
resent haematopoietic progenitors [132] and mature circulating
ECs [39]. Moreover, to date, it has not been carefully addressed
whether the CD34VEGFR-2 phenotype contains the CEPCs that
generate EOCs in vitro. Therefore, the search for a novel marker,
or unique combination of markers and parameters that accurately
discriminates CECs from CEPCs or high proliferative vessel wall
ECs with flow cytometry is mandatory.
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Summary
We have highlighted several areas of controversy that persist in
the study of EPC biology. While significant progress has been
made in our understanding that neovasculogenesis is a multicel-
lular event, and is unlikely to occur from a single recruited progen-
itor cell type, further progress will require the development of
novel assays and conscientious read-out criteria that specifically
identify the functional ability of putative EPCs to directly partici-
pate in postnatal vasculogenesis. Without a standard set of in vitro
and in vivo assays that allow one to allocate specific cell pheno-
typic profiles with specific activities, the field of EPC biology may
stagnate. One can only look at the tremendous clinical advance-
ments made in the field of HSC transplantation that occurred once
both in vitro and in vivo assays were established, that strictly
defined the hierarchical staged development of haematopoietic
precursors, as a paradigm for the progress in clinical applications
of EPCs to cardiovascular disorders that may follow the develop-
ment of similar assays to define neoangiogenesis.
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